PSMA PET parameters predict biochemical recurrence in high-risk prostate cancer after neoadjuvant hormonal therapy
PET scan measures may help predict prostate cancer recurrence after hormone therapy
A phase II RCT of 89 high-risk primary prostate cancer patients found that posttreatment PSMA-expressing volume and pretreatment metastatic …
A specialized PET scan after hormone therapy can predict which high-risk prostate cancer patients face a higher risk of their disease return…
Metabolomics meta-analysis finds metabolites associated with prostate cancer risk, including lethal disease
Could a simple blood test one day predict aggressive prostate cancer?
A systematic review and meta-analysis of 12 observational studies examined associations between pre-diagnostic circulating metabolites and p…
A blood test could one day predict lethal prostate cancer, with 19 specific molecules linked to risk and 13 potentially modifiable by diet o…
Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
Can a targeted radiation treatment help men with advanced prostate cancer?
A prospective, single-arm phase II study of 48 PSMA-avid mCRPC patients treated with 177Lu-PSMA-617 found a 50% PSA response rate and median…
A targeted radiation therapy helped half of men with advanced prostate cancer lower their cancer markers and kept nearly 88% alive after one…
Ga-PSMA-11 PET/CT staging predicts outcomes in unfavorable intermediate- and high-risk prostate cancer
Can a new scan predict prostate cancer outcomes before surgery?
A prospective multicenter trial of 775 patients with newly diagnosed unfavorable intermediate- or high-risk prostate cancer found Ga-PSMA-11…
A new prostate scan predicts survival chances, showing men with distant spread face only 26 percent two-year survival without cancer returni…
Meta-analysis finds 47% PSA decline >50% with Ac-225/Lu-177 PSMA combination in mCRPC
Can a new two-drug radiation combo help men with advanced prostate cancer?
A meta-analysis of 323 patients with mCRPC found that Ac-225/Lu-177 PSMA radioligand combination therapy was associated with a pooled PSA de…
A new two-drug radiation combo helped 78% of men with advanced prostate cancer lower their PSA levels, with nearly half seeing a substantial…
Online rehabilitation program for sexual minority prostate cancer patients shows acceptability but minimal functional improvement
Can an online program help gay men recover sexual function after prostate cancer?
A randomized controlled trial of 401 US sexual minority men with prostate cancer tested an online biopsychobehavioral rehabilitation program…
An online rehab program for gay men after prostate cancer was easy to use but failed to improve sexual or urinary function compared to stand…